First-line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service
- 10 April 2020
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 105 (10), 975-980
- https://doi.org/10.1136/archdischild-2019-318427
Abstract
Background Bronchiolitis is the most common reason for hospital admission in infants. High-flow oxygen therapy has emerged as a new treatment; however, the cost-effectiveness of using it as first-line therapy is unknown. Objective To compare the cost of providing high-flow therapy as a first-line therapy compared with rescue therapy after failure of standard oxygen in the management of bronchiolitis. Methods A within-trial economic evaluation from the health service perspective using data from a multicentre randomised controlled trial for hypoxic infants (≤12 months) admitted to hospital with bronchiolitis in Australia and New Zealand. Intervention costs, length of hospital and intensive care stay and associated costs were compared for infants who received first-line treatment with high-flow therapy (early high-flow, n=739) or for infants who received standard oxygen and optional rescue high-flow (rescue high-flow, n=733). Costs were applied using Australian costing sources and are reported in 2016–2017 AU$. Results The incremental cost to avoid one treatment failure was AU$1778 (95% credible interval (CrI) 207 to 7096). Mean cost of bronchiolitis treatment including intervention costs and costs associated with length of stay was AU$420 (95% CrI −176 to 1002) higher per infant in the early high-flow group compared with the rescue high-flow group. There was an 8% (95% CrI 7.5 to 8.6) likelihood of the early high-flow oxygen therapy being cost saving. Conclusions The use of high-flow oxygen as initial therapy for respiratory failure in infants with bronchiolitis is unlikely to be cost saving to the health system, compared with standard oxygen therapy with rescue high-flow.Keywords
Funding Information
- National Health and Medical Research Council (GNT1081736)
This publication has 19 references indexed in Scilit:
- Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force ReportValue in Health, 2015
- High‐flow nasal cannula oxygen therapy for infants with bronchiolitis: Pilot studyJournal of Paediatrics and Child Health, 2014
- High-flow nasal cannula (HFNC) support in interhospital transport of critically ill childrenIntensive Care Medicine, 2014
- Trends in Bronchiolitis Hospitalizations in the United States, 2000–2009PEDIATRICS, 2013
- Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trialThe Lancet Respiratory Medicine, 2013
- Use of heated humidified high‐flow nasal cannula oxygen in neonates: a UK wide surveyActa Paediatrica, 2012
- Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literatureIntensive Care Medicine, 2012
- What are the current indications for noninvasive ventilation in children?Current Opinion in Anaesthesiology, 2010
- Bronchiolitis: Recent Evidence on Diagnosis and ManagementPEDIATRICS, 2010
- The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical areaArchives of Disease in Childhood, 2003